Published in Medical Letter on the CDC and FDA, September 10th, 2006
The agreement provides Eucodis, an Austrian biotechnology company with drug development expertise, exclusive European development rights in exchange for an upfront license fee and milestone payments totaling approximately US$2.5 million. Eucodis maintains responsibility for costs associated with formestane cream's phase 2 trial which is set to commence in 2007. The data collected from these trials will meet the requirements for submission to regulatory bodies, including the U.S. Food and Drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.